FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1965146956> ?p ?o ?g. }

• W1965146956 endingPage "219" @default.
• W1965146956 startingPage "203" @default.
• W1965146956 abstract "Myelodysplastic syndrome (MDS) comprises a group of heterogeneous clonal bone marrow disorders leading to peripheral cytopenia(s) and hypercellular marrow in the majority of the patients. The morphology of the cell lines is characterized by dysplastic features in some or all cell lines. The FAB classification has divided MDS in five subgroups, namely (1) RA (refractory anemia); (2) RARS (refractory anemia with ring sideroblasts); (3) CMML (chronic myelomonocytic leukemia); (4) RAEB (refractory anemia with excess blasts); and (5) RAEB-T (refractory anemia with excess blasts in transformation). Myelodysplastic syndrome remains primarily a disease of the elderly. With a reported median age of 74.4 years, patients have a chronic relentless course with complication of cytopenias, and a significant number of MDS patients, especially from the RAEB and RAEB-T categories, end up in acute myeloid leukemic transformation. Cytogenetic abnormalities are present in 40-58% of the cases and can provide not only help in diagnosis, but also understanding regarding the clinical course and prognostic aspect. Management of MDS is quite pragmatic and at this stage far from satisfactory. Various modalities have included use of differentiating agents, aggressive chemotherapy, bone marrow transplant and, more recently, significant interest has been generated in the use of hematopoietic growth factors. Differentiating agent trials have been unrewarding so far; chemotherapy trials have resulted in less benefit and more early toxic deaths, especially in the elderly MDS patients where the disease predominates. Bone marrow transplant appears suitable for some patients who are at a younger age. Salvation from this disease is being searched in the proper usage of hematopoietic growth factors and cytokines. There has been concern, however, that usage of growth factors has led to early and enhanced transformation of these patients to frank acute leukemic states. This concept appears to be somewhat refuted by newer controlled trials with GM-CSF and G-CSF, emphasizing that the acute leukemic transformation is the natural course of the disease and is not hastened by growth factor use. Preliminary studies are also suggesting that a combination of growth factors, especially G-CSF and erythropoietin as compared to chemotherapies, could be more beneficial in prolonging the survival of MDS patients who have progressed to the acute leukemic phase. More studies are needed for the understanding of the pathogenetic mechanism(s) in order to facilitate a more suitable and appropriate management strategy for MDS." @default.
• W1965146956 created "2016-06-24" @default.
• W1965146956 creator A5072600168 @default.
• W1965146956 date "1996-03-01" @default.
• W1965146956 modified "2023-09-23" @default.
• W1965146956 title "Myelodysplastic syndromes in the elderly: The role of growth factors in management" @default.
• W1965146956 cites W121813311 @default.
• W1965146956 cites W1480768564 @default.
• W1965146956 cites W1481581854 @default.
• W1965146956 cites W1528346173 @default.
• W1965146956 cites W1586789350 @default.
• W1965146956 cites W1589881672 @default.
• W1965146956 cites W1756218145 @default.
• W1965146956 cites W1809290747 @default.
• W1965146956 cites W1825082566 @default.
• W1965146956 cites W1843902156 @default.
• W1965146956 cites W1967663757 @default.
• W1965146956 cites W1973034088 @default.
• W1965146956 cites W1974683237 @default.
• W1965146956 cites W1976961774 @default.
• W1965146956 cites W1985416982 @default.
• W1965146956 cites W1991796424 @default.
• W1965146956 cites W1995809475 @default.
• W1965146956 cites W1996459017 @default.
• W1965146956 cites W2002255161 @default.
• W1965146956 cites W2006178295 @default.
• W1965146956 cites W2011989789 @default.
• W1965146956 cites W2015627245 @default.
• W1965146956 cites W2019981852 @default.
• W1965146956 cites W2022106508 @default.
• W1965146956 cites W2024967605 @default.
• W1965146956 cites W2028924492 @default.
• W1965146956 cites W2035180118 @default.
• W1965146956 cites W2035660841 @default.
• W1965146956 cites W2035704570 @default.
• W1965146956 cites W2042970750 @default.
• W1965146956 cites W2044823907 @default.
• W1965146956 cites W2045216843 @default.
• W1965146956 cites W2045507683 @default.
• W1965146956 cites W2046442258 @default.
• W1965146956 cites W2047018446 @default.
• W1965146956 cites W2048791837 @default.
• W1965146956 cites W2049657694 @default.
• W1965146956 cites W2049990674 @default.
• W1965146956 cites W2050214747 @default.
• W1965146956 cites W2062718751 @default.
• W1965146956 cites W2063592703 @default.
• W1965146956 cites W2069358413 @default.
• W1965146956 cites W2076426515 @default.
• W1965146956 cites W2079036256 @default.
• W1965146956 cites W2079767854 @default.
• W1965146956 cites W2082668993 @default.
• W1965146956 cites W2085359490 @default.
• W1965146956 cites W2085622873 @default.
• W1965146956 cites W2089632980 @default.
• W1965146956 cites W2090815639 @default.
• W1965146956 cites W2093702073 @default.
• W1965146956 cites W2094631230 @default.
• W1965146956 cites W2115402396 @default.
• W1965146956 cites W2116596071 @default.
• W1965146956 cites W2130654657 @default.
• W1965146956 cites W2131651077 @default.
• W1965146956 cites W2132027522 @default.
• W1965146956 cites W2145750252 @default.
• W1965146956 cites W2147530468 @default.
• W1965146956 cites W2155355600 @default.
• W1965146956 cites W2157711036 @default.
• W1965146956 cites W2161626968 @default.
• W1965146956 cites W2167166475 @default.
• W1965146956 cites W2211072972 @default.
• W1965146956 cites W2256927828 @default.
• W1965146956 cites W2259235546 @default.
• W1965146956 cites W2259922396 @default.
• W1965146956 cites W2262642532 @default.
• W1965146956 cites W2263914605 @default.
• W1965146956 cites W2328397038 @default.
• W1965146956 cites W2333696219 @default.
• W1965146956 cites W2406378945 @default.
• W1965146956 cites W2410421515 @default.
• W1965146956 cites W2412110846 @default.
• W1965146956 cites W2419306110 @default.
• W1965146956 cites W2464812426 @default.
• W1965146956 cites W2952295078 @default.
• W1965146956 cites W3024188003 @default.
• W1965146956 cites W3136565459 @default.
• W1965146956 cites W4235175980 @default.
• W1965146956 cites W4235775400 @default.
• W1965146956 cites W4236104993 @default.
• W1965146956 cites W4240390951 @default.
• W1965146956 cites W4241614974 @default.
• W1965146956 cites W4253916874 @default.
• W1965146956 cites W48378067 @default.
• W1965146956 doi "https://doi.org/10.1016/0145-2126(95)00131-x" @default.
• W1965146956 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8637215" @default.
• W1965146956 hasPublicationYear "1996" @default.
• W1965146956 type Work @default.
• W1965146956 sameAs 1965146956 @default.
• W1965146956 citedByCount "23" @default.

• next